Overexpression of Prohibitin 2 Protein is Associated with Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Cytogenetically normal acute myeloid leukemia (CN-AML) accounts for 40%–50% of all AML cases. Despite advances in understanding the molecular pathophysiology of CN-AML, its clinical outcome remains unsatisfactory and unpredictable. To investigate its clinical implication in CN-AML, we measured the expression of prohibitin 2 (PHB2) using immunohistochemical staining (IHCS) of paraffin-embedded bone marrow sections from 134 CN-AML patients. IHCS results were semi-quantitatively scored. Clinical outcome was analyzed in comparison with other prognostic markers, including NPM1 polymorphism and FLT3 internal tandem duplication, and WT1 and BAALC mRNA expression. Except for BAALC mRNA expression, the known molecular markers showed no prognostic effect in the CN-AML patients. PHB2 protein overexpression was significantly associated with adverse prognosis in CN-AML patients. The PHB2 protein expression status may serve as an independent prognostic indicator in CN-AML.
Abstract
Cytogenetically normal acute myeloid leukemia (CN-AML) accounts for 40%–50% of all AML cases. Despite advances in understanding the molecular pathophysiology of CN-AML, its clinical outcome remains unsatisfactory and unpredictable. To investigate its clinical implication in CN-AML, we measured the expression of prohibitin 2 (PHB2) using immunohistochemical staining (IHCS) of paraffin-embedded bone marrow sections from 134 CN-AML patients. IHCS results were semi-quantitatively scored. Clinical outcome was analyzed in comparison with other prognostic markers, including NPM1 polymorphism and FLT3 internal tandem duplication, and WT1 and BAALC mRNA expression. Except for BAALC mRNA expression, the known molecular markers showed no prognostic effect in the CN-AML patients. PHB2 protein overexpression was significantly associated with adverse prognosis in CN-AML patients. The PHB2 protein expression status may serve as an independent prognostic indicator in CN-AML.
참고문헌 (13)
- Park Mi Suk, "Phospholipase C Beta 2 Protein Overexpression Is a Favorable Prognostic Indicator in Newly Diagnosed Normal Karyotype Acute Myeloid Leukemia", Annals of Laboratory Medicine, 41(4), pp.409~413 (2021), 대한진단검사의학회[DOI]
- Nargess Arandi, "Overexpression of indoleamine 2,3-dioxygenase correlates with regulatory T cell phenotype in acute myeloid leukemia patients with normal karyotype", Blood Research, 53(4), pp.294~298 (2018), 대한혈액학회
- Schlenk RF, "Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia", N Engl J Med, 358, pp.1909~1918 (2008)
- Walker A, "Molecular prognostic factors in cytogenetically normal acute myeloid leukemia", Expert Rev Hematol, 5, pp.547~558 (2012)
- Mawad R, "Acute myeloid leukemia with normal cytogenetics", Curr Oncol Rep, 14, pp.359~368 (2012)
- Kayser S, "Clinical implication of molecular markers in acute myeloid leukemia", Eur J Haematol, 102, pp.20~35 (2019)
- Swerdlow SH, "WHO classification of tumours of haematopoietic and lymphoid tissues" (2008), International Agency for Research on Cancer
- Döhner H, "Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet", Blood, 115, pp.453~474 (2010)
- Signorile A, "Prohibitins : a critical role in mitochondrial functions and implication in diseases", Cells, 8, pp.71~ (2019)
- Kim H-R, "Discovery of a new molecular marker, prohibitin, and development of candidates for new chemotherapeutic agents targeting prohibitin in primary AML cells", Blood, 112, pp.3342~ (2008)
- Ross JA, "The prohibitin protein complex promotes mitochondrial stabilization and cell survival in hematologic malignancies", Oncotarget, 8, pp.65445~65456 (2017)
- Shen Y, "Prohibitin-2 negatively regulates AKT2 expression to promote prostate cancer cell migration", Int J Mol Med, 41, pp.1147~1155 (2018)
- Kim DM, "Beta-catenin induces expression of prohibitin gene in acute leukemic cells", Oncol Rep, 37, pp.3201~3208 (2017)